MedTrace Logo

eVusheld Assessment reaL wORld Effectiveness at UPMC

NCT05667116 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4232

Last updated 2024-11-12

No results posted yet for this study

Summary

An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EUA-eligible patient population in the University of Pittsburgh Medical Center (UPMC) Health System.

Conditions

  • SARS-CoV-2, COVID-19

Interventions

DRUG

EVUSHELD

EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)

Sponsors & Collaborators

  • University of Pittsburgh

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Donald M Yealy, MD · University of Pittsburgh

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-09
Primary Completion
2023-07-24
Completion
2023-07-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05667116 on ClinicalTrials.gov